Literature DB >> 11591749

CD4(+)CD25(+) T cells facilitate the induction of T cell anergy.

J Ermann1, V Szanya, G S Ford, V Paragas, C G Fathman, K Lejon.   

Abstract

T cell anergy is characterized by the inability of the T cell to produce IL-2 and proliferate. It is reversible by the addition of exogenous IL-2. A similar state of unresponsiveness is observed when the proliferative response of murine CD4(+)CD25(-) T cells is suppressed in vitro by coactivated CD4(+)CD25(+) T cells. We have developed a suppression system that uses beads coated with anti-CD3 and anti-CD28 Abs as surrogate APCs to study the interaction of CD4(+)CD25(+) and CD4(+)CD25(-) T cells in vitro. CD4(+)CD25(+) T cell-induced suppression, in this model, was not abrogated by blocking the B7-CTLA-4 pathway. When the CD4(+)CD25(-) T cells were separated from the CD4(+)CD25(+) suppressor cells after 24 h of coactivation by the Ab-coated beads, the CD4(+)CD25(-) T cells were unable to proliferate or to produce IL-2 upon restimulation. The induction of this anergic phenotype in the CD4(+)CD25(-) T cells correlated with the up-regulated expression of the gene related to anergy in lymphocytes (GRAIL), a novel anergy-related gene that acts as a negative regulator of IL-2 transcription. This system constitutes a novel mechanism of anergy induction in the presence of costimulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11591749     DOI: 10.4049/jimmunol.167.8.4271

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease.

Authors:  Silke Paust; Linrong Lu; Nami McCarty; Harvey Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-02       Impact factor: 11.205

2.  Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells.

Authors:  Steven J Bensinger; Patrick T Walsh; Jidong Zhang; Martin Carroll; Ramon Parsons; Jeffrey C Rathmell; Craig B Thompson; Matthew A Burchill; Michael A Farrar; Laurence A Turka
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

Review 3.  CD4+ CD25+ Treg: divide and rule?

Authors:  Lucy S K Walker
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

Review 4.  Dietary agents in cancer prevention: an immunological perspective.

Authors:  Ya Ying Zheng; Bharathi Viswanathan; Pravin Kesarwani; Shikhar Mehrotra
Journal:  Photochem Photobiol       Date:  2012-03-30       Impact factor: 3.421

Review 5.  Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.

Authors:  Doreen Haase; Mireille Starke; Kia Joo Puan; Tuck Siong Lai; Olaf Rotzschke
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 6.  GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness.

Authors:  Chan C Whiting; Leon L Su; Jack T Lin; C Garrison Fathman
Journal:  FEBS J       Date:  2010-11-16       Impact factor: 5.542

7.  Analysis of adhesion molecules, target cells, and role of IL-2 in human FOXP3+ regulatory T cell suppressor function.

Authors:  Dat Q Tran; Deborah D Glass; Gulbu Uzel; Dirk A Darnell; Christine Spalding; Steven M Holland; Ethan M Shevach
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 8.  To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.

Authors:  Jessica E Thaxton; Zihai Li
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-14       Impact factor: 7.638

10.  Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP.

Authors:  Renata Mazzucchelli; Julie A Hixon; Rosanne Spolski; Xin Chen; Wen Qing Li; Veronica L Hall; Jami Willette-Brown; Arthur A Hurwitz; Warren J Leonard; Scott K Durum
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.